Virginia · 2025 Regular Session · Bill
HB 2106: Health insurance; prohibits pharmacy override for enrollee with sickle cell disease.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HB 2106 is a bill introduced in the Virginia House on January 7, 2025. According to its official title, it concerns: Health insurance; prohibits pharmacy override for enrollee with sickle cell disease. Primary sponsor: Otto Wachsmann (Republican). Most recent recorded action (February 5, 2025): Left in Labor and Commerce.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Health insurance; pharmacy override for enrollee with sickle cell disease; prohibited. Prohibits a health insurance carrier from requiring a pharmacy to override a denial code or to request an override in order to dispense a prescription drug for the treatment or management of pain to an enrollee who has been diagnosed with sickle cell disease.
Sponsors
Sponsors by party (alphabetical): Republican 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Otto Wachsmann | Primary sponsor | Republican | House | 83 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Left in Labor and Commerce
- Subcommittee recommends laying on the table (4-Y 3-N)
- Assigned L & C sub: Subcommittee #1
- Referred to Committee on Labor and Commerce
- Prefiled and ordered printed; Offered 01-13-2025 25101618D